First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma

BACKGROUND: The randomized phase 3 CeTeG/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosed MGMT promoter methylated glioblastoma patients. Survival was significantly improved from 31.4 months (temozolomide) to 48.1 months (CCNU plus temozolomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazaridis, Lazaros, Bumes, Elisabeth, Cäcilia Spille, Dorothee, Schulz, Tim, Heider, Sina, Agkatsev, Sarina, Schmidt, Teresa, Blau, Tobias, Oster, Christoph, Feldheim, Jonas, Stummer, Walter, Kessler, Almuth Friederike, Seidel, Clemens, Grauer, Oliver, Hau, Peter, Sure, Ulrich, Keyvani, Kathy, Herrlinger, Ulrich, Kleinschnitz, Christoph, Stuschke, Martin, Herrmann, Ken, Deuschl, Cornelius, Breuer, Stella, Hattingen, Elke, Scheffler, Björn, Kebir, Sied, Glas, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583686/
https://www.ncbi.nlm.nih.gov/pubmed/36284931
http://dx.doi.org/10.1093/noajnl/vdac137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583686/
https://www.ncbi.nlm.nih.gov/pubmed/36284931
http://dx.doi.org/10.1093/noajnl/vdac137

Ejemplares similares